Cryoport and BioLife Cellular Therapy Services, part of the global biopharma company, Takeda Pharmaceutical Company, have joined forces in a strategic relationship to establish an integrated supply chain platform to offer standardized cell therapy collection, processing, storage, and distribution services. The platform will provide consistent, high-quality cellular starting material for use in the manufacture of life-saving cellular therapies. The relationship aims to shorten processing & logistics time and standardize collections to accelerate cell therapy programs.